131.93
Repligen Corp stock is traded at $131.93, with a volume of 850.44K.
It is up +0.69% in the last 24 hours and up +15.53% over the past month.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
See More
Previous Close:
$131.03
Open:
$132.06
24h Volume:
850.44K
Relative Volume:
1.02
Market Cap:
$7.44B
Revenue:
$738.26M
Net Income/Loss:
$48.89M
P/E Ratio:
152.61
EPS:
0.8645
Net Cash Flow:
$91.69M
1W Performance:
+10.15%
1M Performance:
+15.53%
6M Performance:
-11.76%
1Y Performance:
+4.19%
Repligen Corp Stock (RGEN) Company Profile
Name
Repligen Corp
Sector
Industry
Phone
(781) 449-9560
Address
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
RGEN
Repligen Corp
|
131.93 | 7.39B | 738.26M | 48.89M | 91.69M | 0.8645 |
|
ISRG
Intuitive Surgical Inc
|
468.36 | 165.94B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
155.52 | 44.30B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
80.73 | 38.96B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
MDLN
Medline Inc
|
47.93 | 38.69B | 28.43B | 1.16B | 1.26B | 1.4457 |
|
RMD
Resmed Inc
|
228.80 | 33.61B | 5.40B | 1.49B | 1.78B | 10.12 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Initiated | HSBC Securities | Buy |
| Sep-22-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-29-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | Evercore ISI | In-line |
| Feb-10-25 | Initiated | TD Cowen | Buy |
| Dec-17-24 | Initiated | Canaccord Genuity | Hold |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-26-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jun-18-24 | Initiated | Guggenheim | Neutral |
| Dec-04-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-20-23 | Initiated | Wells Fargo | Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Mar-28-23 | Initiated | The Benchmark Company | Buy |
| Dec-14-22 | Initiated | Deutsche Bank | Hold |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-22 | Initiated | UBS | Buy |
| Oct-14-21 | Initiated | Exane BNP Paribas | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| May-07-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-23-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Nov-01-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Oct-15-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-19 | Reiterated | First Analysis Sec | Outperform |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jul-22-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-17-18 | Upgrade | CL King | Neutral → Buy |
| Nov-12-18 | Downgrade | CL King | Buy → Neutral |
| Sep-26-18 | Initiated | H.C. Wainwright | Neutral |
| Dec-08-17 | Initiated | Citigroup | Buy |
| Dec-05-17 | Initiated | JP Morgan | Overweight |
| Nov-13-17 | Initiated | CL King | Buy |
| Oct-02-17 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Jul-21-17 | Initiated | William Blair | Outperform |
| Feb-13-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Repligen Corp Stock (RGEN) Latest News
Repligen Corp (RGEN) Stock Up 6.9% and Still Undervalued -- GF S - GuruFocus
Repligen Corp stock (US7607591002): Is bioprocessing demand strong enough to unlock new upside? - AD HOC NEWS
Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance
RGEN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analyst Lowers Price Target for RGEN Amid Continued Outperform R - GuruFocus
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance Australia
Repligen (RGEN) Valuation Check After Mixed Share Price Returns And High P/E Multiple - Yahoo Finance
Repligen Corp (RGN.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Repligen Corp at Leerink Global Healthcare Conference Transcript - GuruFocus
Repligen (NASDAQ: RGEN) details 2025 growth, CEO pay and governance in 2026 proxy - stocktitan.net
Repligen Corporation (RGEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Are Options Investors Anticipating Significant Movement in Repligen Shares? - Bitget
Are Options Traders Betting on a Big Move in Repligen Stock? - Zacks Investment Research
Will Repligen Corporation face regulatory challenges2026 Intraday Action & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Repligen Corp (RGEN) Stock Price Quote Today & Current Price Chart - capital.com
Repligen Corp (RGEN) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Repligen Corp Stock: Bioprocessing Leader with Strong Growth in Biopharma Supply Chain - AD HOC NEWS
RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know - Yahoo Finance
Repligen Corp (RGEN) Trading Down 3.38% on Mar 27 - GuruFocus
Vanguard amends Schedule 13G/A for Repligen (RGEN): reports 0 shares - Stock Titan
Repligen (RGEN) Down 13.5% Since Last Earnings Report: Can It Rebound? - finance.yahoo.com
RGEN PE Ratio & Valuation, Is RGEN Overvalued - Intellectia AI
E. Ohman J or Asset Management AB Takes Position in Repligen Corporation $RGEN - MarketBeat
Repligen (RGEN) SVP R&D Ralf Kuriyel receives new stock options and RSUs - Stock Titan
Repligen (RGEN) CEO receives 25,890 options and 24,134 RSUs - Stock Titan
Repligen (NASDAQ: RGEN) COO granted options and 7,751 RSUs - Stock Titan
Repligen (RGEN) CFO awarded stock options and 7,751 restricted stock units - Stock Titan
RGEN: HC Wainwright & Co. Raises Price Target for Repligen | RGE - GuruFocus
H.C. Wainwright raises Repligen stock price target on strong growth By Investing.com - Investing.com Canada
H.C. Wainwright raises Repligen stock price target on strong growth - Investing.com
Repligen (NASDAQ:RGEN) Price Target Raised to $208.00 - MarketBeat
Hudson Bay Capital Management LP Invests $2.81 Million in Repligen Corporation $RGEN - MarketBeat
Repligen Conference: CEO touts differentiated bioprocessing portfolio; CFO targets 30% EBITDA margin - Yahoo Finance
Republic Services Inc stock shines with eighth World's Most Ethical Companies honor and analyst upgr - AD HOC NEWS
Repligen Corp stock drops 3.17% on NASDAQ amid biotech sector pressures and upcoming earnings - AD HOC NEWS
Repligen Earnings Beat Puts Focus On Analytics Growth And Rich Valuation - Yahoo Finance
Alliancebernstein L.P. Buys 197,778 Shares of Repligen Corporation $RGEN - MarketBeat
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack - Yahoo Finance
270,000 Shares in Repligen Corporation $RGEN Acquired by Iron Triangle Partners LP - MarketBeat
Fred Alger Management LLC Boosts Position in Repligen Corporation $RGEN - MarketBeat
Repligen Corporation $RGEN Shares Acquired by Bamco Inc. NY - MarketBeat
Schroder Investment Management Group Purchases 254,212 Shares of Repligen Corporation $RGEN - MarketBeat
Repligen Corporation $RGEN Shares Sold by Blue Whale Capital LLP - MarketBeat
Repligen at Leerink Conference: Strategic Growth and Challenges - Investing.com
Reassessing Repligen (RGEN) Valuation After Sector Pullback And Profitability Concerns - Yahoo Finance
Evaluating Repligen (RGEN) After Sharp Share Price Declines and Conflicting Valuation Signals - Yahoo Finance
Reassessing Repligen (RGEN) Valuation After Healthcare Jobs Shock And Margin Concerns - simplywall.st
Market Moves: Whats the analyst consensus on Repligen Corporation2026 Sentiment & Expert Approved Trade Ideas - baoquankhu1.vn
AMN Healthcare Services, RadNet, Evolent Health, Repligen, and Amphastar Pharmaceuticals Stocks Trade Down, What You Need To Know - Yahoo Finance
Repligen Corporation to Present at Upcoming March Conferences - ChartMill
RGEN SEC FilingsRepligen 10-K, 10-Q, 8-K Forms - Stock Titan
Repligen Corp Stock (RGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):